FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554188839> ?p ?o ?g. }

• W2554188839 endingPage "11" @default.
• W2554188839 startingPage "3" @default.
• W2554188839 abstract "Molecular profiling and the discovery of drugs that target specific activating mutations have allowed the personalization of treatment for non-small cell lung cancer (NSCLC). The epithelial growth factor receptor (EGFR) is frequently over-expressed and/or aberrantly activated in different cancers, including NSCLC. The most common activating mutations of EGFR in NSCLC fall within the tyrosine kinase-binding domain. Three oral EGFR tyrosine kinase inhibitors (TKIs) have been approved by the U.S. Food and Drug Administration (FDA) for first-line use in patients with EGFR mutation-positive NSCLC (exon 19 deletions or exon 21 [L858R] substitution mutations), as detected by an FDA-approved test. However, disease progression is common and is often the result of secondary mutations, of which the EGFR T790M mutation is the most prevalent. Few options were available upon progression until the introduction of osimertinib, a kinase inhibitor that targets the T790M mutation, which was recently approved for use in patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who progressed on or after EGFR TKI therapy. With the introduction of osimertinib, outcomes can now be improved in select patients. Therefore, performing a biopsy at progression to determine the underlying molecular cause of the acquired resistance is important for the enabling of individualized options that may provide the greatest opportunity for improved outcomes. This review discusses the latest updates in molecular testing at progression and outlines treatment options for this difficult-to-treat population.2017;22:3-11 IMPLICATIONS FOR PRACTICE: Although the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)-gefitinib, erlotinib, and afatinib-have changed the treatment paradigm for non-small cell lung cancer among those with EGFR mutation positive disease, most patients experience progression after approximately 12 months of treatment. Until recently, options were limited for patients who progressed, but improvements in molecular profiling and the approval of osimertinib, which targets the resistance mutation T790M, afford the opportunity for improved outcomes in many patients with this mutation. This article explains the options available after progression on initial EGFR TKI therapy and the importance of molecular testing at progression in making treatment decisions." @default.
• W2554188839 created "2016-11-30" @default.
• W2554188839 creator A5078629724 @default.
• W2554188839 creator A5082389042 @default.
• W2554188839 creator A5088559019 @default.
• W2554188839 date "2017-01-01" @default.
• W2554188839 modified "2023-10-16" @default.
• W2554188839 title "Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression" @default.
• W2554188839 cites W1973529979 @default.
• W2554188839 cites W1973946393 @default.
• W2554188839 cites W1978236936 @default.
• W2554188839 cites W1978285367 @default.
• W2554188839 cites W1980497534 @default.
• W2554188839 cites W1981692037 @default.
• W2554188839 cites W1983159571 @default.
• W2554188839 cites W1987283660 @default.
• W2554188839 cites W1987370132 @default.
• W2554188839 cites W1987575156 @default.
• W2554188839 cites W1988827171 @default.
• W2554188839 cites W1990013637 @default.
• W2554188839 cites W1994539763 @default.
• W2554188839 cites W1995831225 @default.
• W2554188839 cites W1998971866 @default.
• W2554188839 cites W2002937040 @default.
• W2554188839 cites W2003984225 @default.
• W2554188839 cites W2005665711 @default.
• W2554188839 cites W2009775937 @default.
• W2554188839 cites W2014484940 @default.
• W2554188839 cites W2022670843 @default.
• W2554188839 cites W2026342389 @default.
• W2554188839 cites W2027242209 @default.
• W2554188839 cites W2027735722 @default.
• W2554188839 cites W2032032056 @default.
• W2554188839 cites W2037353038 @default.
• W2554188839 cites W2043696829 @default.
• W2554188839 cites W2049553585 @default.
• W2554188839 cites W2061932411 @default.
• W2554188839 cites W2076178766 @default.
• W2554188839 cites W2076210779 @default.
• W2554188839 cites W2076466060 @default.
• W2554188839 cites W2083605381 @default.
• W2554188839 cites W2093613683 @default.
• W2554188839 cites W2095504100 @default.
• W2554188839 cites W2095618958 @default.
• W2554188839 cites W2096198395 @default.
• W2554188839 cites W2097560495 @default.
• W2554188839 cites W2099382478 @default.
• W2554188839 cites W2099742478 @default.
• W2554188839 cites W2099814710 @default.
• W2554188839 cites W2104347254 @default.
• W2554188839 cites W2104603750 @default.
• W2554188839 cites W2111662961 @default.
• W2554188839 cites W2119764457 @default.
• W2554188839 cites W2120111652 @default.
• W2554188839 cites W2121110176 @default.
• W2554188839 cites W2121641332 @default.
• W2554188839 cites W2126177831 @default.
• W2554188839 cites W2128208856 @default.
• W2554188839 cites W2128385295 @default.
• W2554188839 cites W2130043727 @default.
• W2554188839 cites W2132870547 @default.
• W2554188839 cites W2136263263 @default.
• W2554188839 cites W2137666600 @default.
• W2554188839 cites W2138089710 @default.
• W2554188839 cites W2139236349 @default.
• W2554188839 cites W2145980885 @default.
• W2554188839 cites W2152481222 @default.
• W2554188839 cites W2153477391 @default.
• W2554188839 cites W2154149901 @default.
• W2554188839 cites W2155744217 @default.
• W2554188839 cites W2159013299 @default.
• W2554188839 cites W2160212814 @default.
• W2554188839 cites W2160982674 @default.
• W2554188839 cites W2161821474 @default.
• W2554188839 cites W2166084034 @default.
• W2554188839 cites W2166261313 @default.
• W2554188839 cites W2171139285 @default.
• W2554188839 cites W2191042712 @default.
• W2554188839 cites W2198093519 @default.
• W2554188839 cites W2205289691 @default.
• W2554188839 cites W2218718059 @default.
• W2554188839 cites W2292338160 @default.
• W2554188839 cites W2292957477 @default.
• W2554188839 cites W2299139004 @default.
• W2554188839 cites W2400514548 @default.
• W2554188839 cites W2478124970 @default.
• W2554188839 cites W2560367415 @default.
• W2554188839 cites W2572174216 @default.
• W2554188839 cites W2747688417 @default.
• W2554188839 cites W2766812085 @default.
• W2554188839 cites W2787353230 @default.
• W2554188839 cites W2890605354 @default.
• W2554188839 cites W2921800184 @default.
• W2554188839 cites W775417740 @default.
• W2554188839 doi "https://doi.org/10.1634/theoncologist.2016-0285" @default.
• W2554188839 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5313265" @default.
• W2554188839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27821794" @default.
• W2554188839 hasPublicationYear "2017" @default.

• next